Appropriately managing the suite of cardiometabolic disorders has substantial clinical implications for cardiovascular health and prevention of cardiovascular disease (CVD). In the case of diabetes, dyslipidemias, and hypertension, achieving the goals of HbA1c <7%, LDL cholesterol <100 mg/dL, and blood pressure <140/90 sets the patient up with significant cardiovascular benefits, such as the prevention of downstream CVD, heart attack, heart failure, or stroke. Although there has always been a “disconnect” between what is known and what is actually done, on both clinician and patient levels, and at times, compromises have to be made to individualize treatments, there is still an awareness of the importance of managing the individual components of cardiometabolic disorders aggressively and effectively.
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More